A phase ii study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis

Haematologica

Volumn 99, Issue 1, 2014, Pages 5-7

  Andersen, Christen L ^a   Mortensen, Nana B ^a   Klausen, Tobias W ^b   Vestergaard, Hanne ^c   Bjerrum, Ole W ^d   Hasselbalch, Hans C ^a  

^a ROSKILDE HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d Rigshospitalet   (Denmark)

Author keywords

Clinical response; Monotherapy; Post polycythemia vera; Primary myelofibrosis; Vorinostat

Indexed keywords

CLINICAL RESPONSE; MONOTHERAPY; POST-POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; VORINOSTAT;

HUMANS; HYDROXAMIC ACIDS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; TREATMENT OUTCOME;

EID: 84892565844     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/Haematol.2013.096669     Document Type: Letter

References (12)

1. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355(23):2452-2466.
2. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342(17):1255-1265.
3. Cervantes F, Dupriez B, Passamonti F, Vannucchi AM, Morra E, Reilly JT, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol. 2012;30(24):2981-2987.
4. Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437-438.
5. Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, Carobbio A, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia. 2008;22(4):740-747.
6. Lee J. Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis. Ann Hematol. 2009;88(7):699-700.
7. Deangelo DJ, Mesa RA, Fiskus W, Tefferi A, Paley C, Wadleigh M, et al. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombo-cythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol. 2013;162(3):326-335.
8. Mascarenhas J, Lu M, Li T, Petersen B, Hochman T, Najfeld V, et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential throm-bocythaemia myelofibrosis (post-PV/ET MF). Br J Haematol. 2013;161(1):68-75.
9. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108(5):1497-1503.
10. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401-408.
11. Tefferi A, Vardiman JW. Classification and diagnosis of myeloprolif-erative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14-22.
12. Andersen CL, McMullin MF, Ejerblad E, Zweegman S, Harrison C, Fernandes S, et al. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2013;162(4):498-508.